Literature DB >> 16542617

Progress, but not yet ready for clinical use: interrupting immune-mediated destruction of pancreatic beta cells in type 1 diabetes.

Carla J Greenbaum1.   

Abstract

Entities:  

Year:  2006        PMID： 16542617     DOI： 10.1007/s11892-006-0017-8

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  6 in total

1.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

Authors:  Kevan C Herold; William Hagopian; Julie A Auger; Ena Poumian-Ruiz; Lesley Taylor; David Donaldson; Stephen E Gitelman; David M Harlan; Danlin Xu; Robert A Zivin; Jeffrey A Bluestone
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

2.  Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes.

Authors:  Carla J Greenbaum; Leonard C Harrison
Journal:  Diabetes       Date:  2003-05       Impact factor: 9.461

3.  CD3-antibody therapy in new-onset type 1 diabetes mellitus.

Authors:  Michael J Haller; Desmond A Schatz
Journal:  N Engl J Med       Date:  2005-11-10       Impact factor: 91.245

4.  Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.

Authors: 
Journal:  Ann Intern Med       Date:  1998-04-01       Impact factor: 25.391

5.  Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.

Authors:  Michael W Steffes; Shalamar Sibley; Melissa Jackson; William Thomas
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

6.  C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

Authors:  Jerry P Palmer; G Alexander Fleming; Carla J Greenbaum; Kevan C Herold; Lisa D Jansa; Hubert Kolb; John M Lachin; Kenneth S Polonsky; Paolo Pozzilli; Jay S Skyler; Michael W Steffes
Journal:  Diabetes       Date:  2004-01       Impact factor: 9.461
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.